請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84364完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林彩瑜(Tsai-Yu Lin) | |
| dc.contributor.author | Chia Yu Yao | en |
| dc.contributor.author | 姚嘉瑜 | zh_TW |
| dc.date.accessioned | 2023-03-19T22:09:29Z | - |
| dc.date.copyright | 2022-09-30 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-09-26 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84364 | - |
| dc.description.abstract | COVID-19大流行的出現導致了貿易政策產生了各種變化,其規模可謂前所未有。各國為了在COVID-19大流行期間維持其公共衛生狀態,也選擇採取了各種貿易措施,而該等措施常常亦是針對大流行所進行的干預性公共衛生措施。在本研究中,該等措施被定義為COVID-19貿易相關的衛生措施。 在各國採取的一系列COVID-19貿易相關的衛生措施,包括影響貨物貿易、服務貿易和智慧財產權貿易的措施之中,本研究發現,對COVID-19必要醫療貨品的出口限制措施,極可能是出於民族主義的考慮,並且也是對自由貿易之維護產生最大威脅的措施類型。從全球衛生的角度來看,由於該等出口限制措施會減少其他需要必要醫療貨品對抗COVID-19疫情的國家獲取該等貨品的機會,其同時也會對全球衛生狀態構成威脅。當COVID-19必要醫療貨品的主要生產國決定對該等貨品實施出口限制時,其負面影響更為明顯。 世界貿易組織(World Trade Organization, WTO)是管制國際貿易措施的主要國際組織。為了確定現有的WTO規則是否能夠約束對COVID-19必要醫療貨品的出口限制措施,本研究選擇了兩個主要生產國,歐盟(European Union, EU)和美國(United States, U.S.),分析現有的WTO規則如何適用於此二國家對COVID-19必要醫療貨品,包含個人防護設備及疫苗,所採取的出口限制措施。 本研究發現,雖然出口限制被WTO一般性地禁止,但仍有排除條款與例外條款,在現有WTO規則下, COVID-19必要醫療貨品的出口限制措施有被允許的可能,此亦包含本研究特別關注的歐盟和美國案例。因此,現有WTO規則似無法處理COVID-19必要醫療貨品的出口限制措施對全球衛生所產生的威脅。此外,雖然在全球衛生法制度下,世界衛生組織(World Health Organization, WHO)所領導的《國際衛生條例》(International Health Regulations, IHR)在一定程度上具備管制貿易相關措施的能力,但其規則和體制兩方面皆有設計上的不足。 本研究提出,雖然貿易問題應主要在WTO規則下解決,但針對COVID-19或未來大流行的必要醫療貨品之出口限制措施,以解決方案的完整性而言,國際貿易和衛生機構的合作有其必要性。在WTO規則上,應針對必要醫療貨品出口限制措施進行特殊規範,並將規範之情形區分為為解決一國公共衛生緊急情況而實施的出口限制措施,以及為協助恢復一國公共衛生狀態而實施的出口限制措施,實施區分性的規範。此外,WTO亦應與WHO在科學評估以及必要醫療貨品出口限制措施的監控上進一步合作,方能更完整地解決實施必要醫療貨品出口限制措施所造成的全球衛生狀態的威脅。 | zh_TW |
| dc.description.abstract | The emergence of the COVID-19 pandemic has led to a never-before-seen scale of change in trade policies. In order to sustain their public health conditions during the COVID-19 pandemics, countries have adopted trade measures which are also epidemic intervening public health measures, defined as COVID-19 trade-related health measures in this study. Among the spectrum of COVID-19 trade-related health measures adopted by countries including those affecting trade in goods, trade in services and trade in intellectual property, it is found that export restrictions on COVID-19 essential medical goods, often adopted with nationalistic concerns, are the most dangerous type of measure to the maintenance of free trade. From a global health perspective, they also pose threat to the overall global health condition since they can negatively affect the accessibility to COVID-19 essential medical goods for other countries needing those goods to combat COVID-19 outbreak. Naturally, the negative effect is especially obvious when major producers decide to impose export restrictions on COVID-19 essential medical goods. The World Trade Organization (WTO) is the main international institution in regulating international trade measures. In order to determine whether existing WTO rules can assist in disciplining export restrictions on COVID-19 medical goods, this study selects two major producers, the European Union (EU) and the United States (U.S.), to study the applicability of existing WTO rules on their export restrictions on COVID-19 medical goods, including examples targeting personal protective equipment and vaccines. It is found in this study that while export restrictions are generally prohibited by the WTO, exemptions and exceptions still exist that there remains a possibility that export restrictions on COVID-19 essential medical goods, including the specific EU and U.S. measures, can be allowed under WTO rules. Such possibility leaves the threat of these measures to further deterioration global health resulting from trade measures unaddressed. In addition, although equipped with a certain extent of capacity to deal with trade measures taken, insufficiencies also exist in the global health law regime in terms of the design of rules and institution led by the International Health Regulations (IHR) under the World Health Organization (WHO). This study proposes that while trade issues should be mainly addressed under WTO rules, cooperation of the international trade and health institutions is necessary to provide a more complete solution to discipline export restrictions on COVID-19 essential medical goods or export restrictions on essential medical goods in future pandemics. The proposed solution within the WTO is to adjust rules specifically applicable for export restrictions on essential medical goods, differentiating between those imposed to resolve a public health emergency, and those imposed to assist in recovery of public health status. Additionally, cooperation with the WHO in scientific assessments and monitoring of export restrictions can further complete and the solution to the threat to global health caused by export restrictions on essential medical goods. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T22:09:29Z (GMT). No. of bitstreams: 1 U0001-2309202217100000.pdf: 4213718 bytes, checksum: 4dfd23a643ca1bf70640fde17095c969 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 誌謝 i 中文摘要 iii ABSTRACT v LIST OF FIGURES xii LIST OF TABLES xiii Chapter 1: Introduction 1 1.1 Background and Objective of the Study 1 1.2 Scope and Limitation of the Study 9 1.2.1 COVID-19 Trade Related Health Measures 9 1.2.2 COVID-19 Essential Medical Goods 11 1.3 Layout of the Thesis 14 Chapter 2: Trade-related Health Measures Responsive to the COVID-19 Pandemics: An Overview 16 2.1 Measures Affecting Trade in Goods 16 2.1.1 Export Restrictions 17 2.1.2 Tariff Reduction or Elimination 18 2.1.3 Import Procedure Revisions 20 2.1.4 Prioritization of Domestic Productions and Expediting Procurement Procedures 22 2.2 Measures Affecting Trade in Services 25 2.2.1 Effect on Tourism and Travel-related Services 29 2.2.2 Effect on Distribution Services 30 2.2.3 Effect on Transport Services 32 2.2.3.1 Effect on Air Transport Services 33 2.2.3.2 Effect on Maritime Transport Services 34 2.2.3.3 Effect on Land Transport Services 36 2.3 Measures Affecting Intellectual Property 38 2.3.1 Domestic Intellectual Property Measures 39 2.3.1.1 Patentability 40 2.3.1.2 Limited Exceptions to Patent Rights 41 2.3.1.3 Compulsory and Government-use Licenses 42 2.3.1.4 Use of LDC Transition Period 49 2.3.1.5 Transfer of Technology 50 2.3.2 International Initiative: COVAX 51 2.3.3 Discussion on the Intellectual Property Waiver 54 2.4 Export Restrictions Result in Greatest Negative Impact on the Global Value Chain of COVID-19 Essential Medical Goods 58 2.4.1 Impact of COVID-19 Trade-related Health Measures on the Global Value Chain 58 2.4.2 Export Restrictions on COVID-19 Essential Medical Goods and the Emergence of Pandemic Nationalism 61 2.5 Conclusion 66 Chapter 3: Export Restrictions on COVID-19 Essential Medical Goods 67 3.1 Export Restrictions Introduced Globally 67 3.2 Major Producer 1: EU Export Control Regime 74 3.2.1 Intra-EU Export Control Regime 74 3.2.2 Extra-EU Export Control Regime 77 3.2.2.1 Export Control on PPEs 77 3.2.2.2 Export Control on Vaccines 83 3.3 Major Producer 2: US Export Control Regime 88 3.3.1 Export Control on PPEs 88 3.3.2 Export Control on Vaccines 93 Chapter 4: Consistency of Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. with GATT Article XI 97 4.1 Scope of Article XI 97 4.1.1 Distinction Between Border Measures versus Domestic Regulations 98 4.1.2 Measures Considered as Quantitative Restrictions 100 4.1.3 De facto Prohibitions or Restriction 103 4.1.4 EU and U.S. COVID-19 Trade-Related Health Measures on PPEs and Vaccines As Quantitative Restrictions on Export 106 4.1.4.1 EU PPE Export Restriction as QR 106 4.1.4.2 EU Vaccine Export Restriction as QR 107 4.1.4.3 U.S. PPE Export Restriction as QR 108 4.1.4.4 U.S. Vaccine Export Restriction as QR 108 4.2 Exemption to Quantitative Restrictions Under GATT Article XI:2(a) 110 4.2.1 How the Drafting History Informs the Meaning of GATT Article XI:2(a) 110 4.2.2 Case Study: China – Raw Materials 111 4.2.2.1 Temporal Limit on Response to a Critical Shortage 112 4.2.2.2 To Prevent or Relieve a Critical Shortage 114 4.2.2.3 Products Essential to the Exporting Member 116 4.3 Non-discrimination Requirement Under GATT Article XIII 119 4.3.1 How Should Export Restrictions Be Allocated Across WTO Members to Be Non-discriminatory? 120 4.3.2 Does GATT Article XXIV Allow Article XIII Inconsistent Measures? 121 4.3.2.1 EC – Bananas 121 4.3.2.2 Turkey – Textiles 123 4.4 Consistency of Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. with GATT Article XI:1 127 4.5 Interim Conclusion 131 Chapter 5: Justifying Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. in Terms of GATT General Exceptions 133 5.1 GATT General Exceptions: Article XX 133 5.2 GATT Article XX(b) 135 5.2.1 Measures “Necessary to Protect Human . . . Life or Health” 135 5.2.1.1 Whether a Measure is Designed to Achieve Its Policy Objective to Protect Human Life or Health 136 5.2.1.2 Consideration of Human Life or Health Outside a Member’s Territory 138 5.2.2 The Necessity Test 140 5.3 GATT Article XX(j) 146 5.3.1 How the Drafting History Informs the Meaning of GATT XX:2(j) 146 5.3.2 Measures Essential to the Acquisition or Distribution of Products in General or Local Short Supply 148 5.3.2.1 “Essential to” 148 5.3.2.2 “Acquisition or Distribution” 150 5.3.2.3 “Products in General or Local Short Supply” 150 5.3.3 Principle of Equitable Share 153 5.3.4 Temporal Limit 155 5.4 Chapeau of GATT Article XX 156 5.4.1 Discrimination Under the Chapeau 157 5.4.2 Arbitrary or Unjustifiable Discrimination 158 5.4.3 Countries Where the Same Conditions Prevail 159 5.4.4 Disguised Restriction on International Trade 160 5.4.5 GATT Article XXIV and Chapeau of Article XX 161 5.5 Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. Under GATT Exceptions 165 5.5.1 Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. Under GATT XX(b) 165 5.5.2 Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. Under GATT XX(j) 169 5.6 Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. Under the Chapeau of GATT Article XX 174 5.6.1 EU PPE Export Restriction Under GATT XX Chapeau 174 5.6.2 EU Vaccines Export Restriction Under GATT XX Chapeau 178 5.6.3 US PPE Export Restriction Under GATT XX Chapeau 179 5.6.4 US Vaccine Export Restriction Under GATT XX Chapeau 181 5.7 Interim Conclusion 183 Chapter 6: Justifying Export Restrictions on COVID-19 Essential Medical Goods by Major Producers EU and U.S. in Terms of GATT Security Exceptions 186 6.1 GATT Security Exceptions: Article XXI 186 6.2 WTO Jurisdiction and Justiciability of “Self-Judging” Security Exceptions 189 6.3 Taken in Time of an Emergency in International Relations 193 6.3.1 An Emergency in International Relations 193 6.3.2 Taken in Time of 196 6.4 Action Which it Considers Necessary for the Protection of its Essential Security Interests 197 6.5 COVID-19 Pandemic as Threat to Essential Security Interest and Emergency in International Relations 200 6.5.1 Pandemic as Threat to Essential Security Interest 200 6.5.2 COVID-19 Pandemic as Emergency in International Relations 201 6.6 Application of Security Exception on Export Restrictions: U.S. PPE as an Example 204 6.7 Interim Conclusion 207 Chapter 7: Future Approach to Export Restrictions on Essential Medical Goods in Pandemic-like Situations: COVID-19 as an Example 209 7.1 Limited Effect of WTO Rules in Regulating Export Restrictions on COVID-19 Essential Medical Goods 209 7.1.1 GATT Article XI:2(a) versus Article XX(b) 209 7.1.2 GATT Article XI:2(a) versus Article XX(j) 211 7.1.3 Limits of GATT Article XXI(b)(iii) 213 7.1.4 WTO Rules Ensuring Transparency and the Lack Thereof for Export Restrictions on COVID-19 Essential Medical Goods 214 7.1.5 Challenges of WTO Rules to Export Restrictions on COVID-19 Essential Medical Goods 216 7.2 Limited Effect of WHO Rules in Regulating Export Restrictions on COVID-19 Essential Medical Goods 219 7.2.1 WHO and the International Health Regulations (2005) 219 7.2.2 Overview of the IHR and its Trade Interest Concerns 220 7.2.3 Public Health Risks Response Framework of the IHR 222 7.2.3.1 Disease Surveillance and Response and Building of National Core Capacities 224 7.2.3.2 Notification Obligations and Information Verification 224 7.2.3.3 Declaration of PHEICs 226 7.2.4 Article 43: Main Article Addressing Trade Concerns Under the IHR 227 7.2.5 Limited Effect of IHR in Regulating Export Restrictions on COVID-19 Essential Medical Goods 228 7.3 International Initiatives to Regulate Export Restrictions on COVID-19 Essential Medical Goods 231 7.3.1 G20 Trade and Investment Ministerial Statement 231 7.3.2 Singapore-New Zealand Declaration on Trade in Essential Goods for Combating the COVID-19 Pandemic 232 7.3.3 APEC Declaration on Facilitating the Movement of Essential Goods 2020 and Ministers Responsible for Trade Meeting Joint Statement 2021 233 7.3.4 Ottawa Group: Action on COVID-19 and WTO Trade and Health Initiative 236 7.4 Regulating Export Restrictions on COVID-19 Essential Medical Goods and Outlook for Future Pandemic 240 7.4.1 Latest Development: WTO’s 12th Ministerial Conference (MC12) 240 7.4.2 The Main Concerns of Regulation of Export Restrictions on COVID-19 Essential Medical Goods 243 7.4.3 Differentiating Regulation of Export Restrictions on COVID-19 Essential Medical Goods: Resolving an Emergency versus Road to Recovery 245 7.4.3.1 Export Restrictions Resolving a Public Health Emergency 245 7.4.3.2 Export Restrictions on Road to Recovery: The Case of Vaccines 247 7.4.4 Other Concerns to Be Resolved Under Co-operation With the WHO 249 7.4.5 Feasibility in Finding a Consensus in Negotiations to Realize Proposed Regulation for Export Restrictions on COVID-19 Essential Medical Goods 252 7.5 Conclusion 256 REFERENCES 263 | |
| dc.language.iso | en | |
| dc.subject | WHO | zh_TW |
| dc.subject | 關稅暨貿易總協定 | zh_TW |
| dc.subject | 出口限制 | zh_TW |
| dc.subject | WTO | zh_TW |
| dc.subject | 大流行 | zh_TW |
| dc.subject | COVID-19 | zh_TW |
| dc.subject | 國際衛生條例 | zh_TW |
| dc.subject | WHO | en |
| dc.subject | International Health Regulations | en |
| dc.subject | GATT | en |
| dc.subject | export restriction | en |
| dc.subject | WTO | en |
| dc.subject | pandemic | en |
| dc.subject | COVID-19 | en |
| dc.title | COVID-19必要醫療貨品出口限制措施所涉WTO法律問題之研究 | zh_TW |
| dc.title | Regulating Export Restrictions on COVID-19 Essential Medical Goods Under WTO Law | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳在方(Tsai-Fang Chen),薛景文(Ching-Wen Hsueh) | |
| dc.subject.keyword | COVID-19,大流行,WTO,出口限制,關稅暨貿易總協定,WHO,國際衛生條例, | zh_TW |
| dc.subject.keyword | COVID-19,pandemic,WTO,export restriction,GATT,WHO,International Health Regulations, | en |
| dc.relation.page | 274 | |
| dc.identifier.doi | 10.6342/NTU202203938 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-09-27 | |
| dc.contributor.author-college | 法律學院 | zh_TW |
| dc.contributor.author-dept | 科際整合法律學研究所 | zh_TW |
| dc.date.embargo-lift | 2022-09-30 | - |
| 顯示於系所單位: | 科際整合法律學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2309202217100000.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 4.11 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
